Verona Pharma: Start of RPL554 Phase IIa combination study

Verona Pharma plc , the drug development company focused on first-in-class medicines to treat respiratory diseases, has announced that the first patients have been dosed in a Phase IIa combination study to evaluate the addition of RPL554 to standard reliever medications for chronic obstructive pulmonary disease (COPD).

Read more